Allarity Therapeutics, Inc. (ALLR) stock
Close on Nov 12, 2026Market cap $14.54MP/E –Yield –
Allarity Therapeutics, Inc. reported revenue of $320.00K for fiscal 2025. Free cash flow was -$14.83M. At the latest close the market valued the company at $14.54M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $14.54M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 4.11
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $320.00K
- Net income
- -$12.33M
- EPS, diluted
- -$0.78
- Free cash flow
- -$14.83M
- Book value per share
- $0.22
- Diluted shares
- 16M
Trading
- Previous close
- $0.94
- Open
- $0.93
- Day's range
- $0.88 – $0.97
- Volume
- 78,066
- Average volume (20 days)
- 128,380
- Beta (5 years)
- 1.11
- 52-week range
- $0.77 – $1.84
- RSI (14 days)
- 45.2
- Volatility (1 year)
- 78.4%
- Relative volume
- 0.73×
- WACC
- 6.7%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ALLR | S&P 500 | Difference | ALLR per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +6.2% | -2.7% | +8.9 pts | ||
| 3 months | -34.7% | -1.7% | −33.0 pts | ||
| Year to date | -15.4% | +11.9% | −27.3 pts | ||
| 1 year | -28.0% | +12.0% | −40.0 pts | ||
| 3 years | -99.7% | +78.2% | −177.9 pts | -85.2% | +21.2% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Allarity Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- News
- News
- Results
About Allarity Therapeutics
Pharmaceutical Preparations
Allarity Therapeutics is a clinical-stage precision medicine pharmaceutical company developing targeted cancer therapeutics. The company focuses on its lead therapeutic candidate, stenoparib, a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) and tankyrases being evaluated in clinical trials for advanced ovarian cancer and relapsed small cell lung cancer. In conjunction with drug development, the business utilizes its proprietary Drug Response Predictor (DRP) companion diagnostic platform to identify patients most likely to benefit from specific treatments. It also provides DRP analysis and gene expression laboratory services to external biotechnology clients.
Company profile, executives and historyAllarity Therapeutics stock: common questions
What is Allarity Therapeutics's stock price?
ALLR closed at $0.91 on Nov 12, 2026, down 2.30% on the day. Over the past 52 weeks it traded between $0.77 and $1.84.
What is Allarity Therapeutics's market cap?
Allarity Therapeutics was worth $14.54M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ALLR's P/E ratio?
Allarity Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.78), so it has no meaningful P/E ratio.
How much revenue does Allarity Therapeutics make?
Allarity Therapeutics reported revenue of $320.00K for fiscal 2025.
Does Allarity Therapeutics pay a dividend?
No. Allarity Therapeutics has not paid a cash dividend over the last twelve months.
How has ALLR stock performed over the past year?
Including dividends, ALLR returned -28.0% over the past year, against +12.0% for the S&P 500.
How many ALLR shares are sold short?
0M shares were sold short at the latest FINRA report, 1.55% of the float, or 1.9 days of average trading volume.
Who are Allarity Therapeutics's competitors?
Companies most similar to Allarity Therapeutics by business, industry and size include PVCT, SCNX, MREO, LSTA, INO.
See a number that looks wrong?